Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study.

Tsubouchi N, Uto H, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Oketani M, Ido A, Hayashi K, Kusumoto K, Shimoda K, Stuver SO, Tsubouchi H.

Hepatol Res. 2013 Nov;43(11):1130-8. doi: 10.1111/hepr.12075. Epub 2013 Feb 18.

2.

Associations between antibody to hepatitis B core antigen positivity and outcomes in hepatocellular carcinoma patients undergoing hepatic resection.

Itoh S, Yoshizumi T, Tomino T, Nagatsu A, Motomura T, Harada N, Harimoto N, Ikegami T, Soejima Y, Maehara Y.

Hepatol Res. 2018 Feb;48(3):E155-E161. doi: 10.1111/hepr.12939. Epub 2017 Sep 28.

PMID:
28710825
3.

Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.

Laguno M, Larrousse M, Blanco JL, Leon A, Milinkovic A, Martínez-Rebozler M, Loncá M, Martinez E, Sanchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.

AIDS Res Hum Retroviruses. 2008 Apr;24(4):547-53. doi: 10.1089/aid.2007.9994.

PMID:
18393687
5.

High Frequency of Hepatitis B Core and Surface Antibodies in Hepatitis C Virus-Infected Patients on the Screening Examination.

Suto C, Murakami H, Kobayashi Y, Nagamine T, Saitoh T, Kasamatsu T, Ogawara H, Murakami M.

Rinsho Byori. 2015 Mar;63(3):305-11.

PMID:
26524852
6.

Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.

Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K.

Scand J Gastroenterol. 2008;43(7):849-56. doi: 10.1080/00365520801935459.

PMID:
18584524
7.

HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.

Momosaki S, Nakashima Y, Kojiro M, Tabor E.

J Viral Hepat. 2005 May;12(3):325-9.

PMID:
15850475
8.

A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.

Zhang JY, Dai M, Wang X, Lu WQ, Li DS, Zhang MX, Wang KJ, Dai LP, Han SG, Zhou YF, Zhuang H.

Int J Epidemiol. 1998 Aug;27(4):574-8.

PMID:
9758109
9.
10.

Markers of hepatitis B infection in Tari District, Southern Highlands Province, Papua New Guinea.

Sanders RC, Lewis D, Dyke T, Alpers MP.

P N G Med J. 1992 Sep;35(3):197-201.

PMID:
1296422
11.

Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.

Attia KA, Eholié S, Messou E, Danel C, Polneau S, Chenal H, Toni T, Mbamy M, Seyler C, Wakasugi N, N'dri-Yoman T, Anglaret X.

World J Hepatol. 2012 Jul 27;4(7):218-23. doi: 10.4254/wjh.v4.i7.218.

12.

Outcomes of liver transplantation in simultaneously hepatitis B surface antigen and hepatitis C virus RNA positive recipients: the deleterious effect of donor hepatitis B core antibody positivity.

Tandoi F, Romagnoli R, Martini S, Mazza E, Nada E, Cocchis D, Lupo F, Salizzoni M.

Transplant Proc. 2012 Sep;44(7):1960-2. doi: 10.1016/j.transproceed.2012.07.061.

PMID:
22974882
13.

Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease.

Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ Jr, Kuo PC, Keay S, Oldach DW.

Transplantation. 1997 Dec 27;64(12):1781-6.

PMID:
9422420
14.

Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and Lamivudine.

Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, Kelley M, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3187-9.

PMID:
16213345
15.

Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan?

Shiratori Y, Shiina S, Zhang PY, Ohno E, Okudaira T, Payawal DA, Ono-Nita SK, Imamura M, Kato N, Omata M.

Cancer. 1997 Dec 1;80(11):2060-7.

PMID:
9392327
16.

Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection.

Omichi K, Shindoh J, Yamamoto S, Matsuyama Y, Akamatsu N, Arita J, Kaneko J, Sakamoto Y, Hasegawa K, Kokudo N.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1034-40. doi: 10.1245/s10434-015-4845-0. Epub 2015 Sep 8.

PMID:
26350363
17.

Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan.

Oda K, Uto H, Kumagai K, Ido A, Kusumoto K, Shimoda K, Hayashi K, Stuver SO, Tanaka Y, Nishida N, Tokunaga K, Tsubouchi H.

J Med Virol. 2014 Nov;86(11):1877-85. doi: 10.1002/jmv.24037. Epub 2014 Aug 7.

PMID:
25100136
18.
19.

Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.

Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS.

J Rheumatol. 2010 Feb;37(2):346-50. doi: 10.3899/jrheum.090436. Epub 2009 Dec 15.

PMID:
20008922
20.

Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study.

Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M, Tsubouchi H.

Hepatology. 2009 Aug;50(2):393-9. doi: 10.1002/hep.23002.

Supplemental Content

Support Center